1.Efficacy of Dendritic Cells Matured Early with OK-432 (Picibanil(R)), Prostaglandin E2, and Interferon-alpha as a Vaccine for a Hormone Refractory Prostate Cancer Cell Line.
Changhee YOO ; Hyun Ah DO ; In Gab JEONG ; Hongzoo PARK ; Jung Jin HWANG ; Jun Hyuk HONG ; Jin Seon CHO ; Myong Soo CHOO ; Hanjong AHN ; Choung Soo KIM
Journal of Korean Medical Science 2010;25(9):1284-1290
Dendritic cells (DCs) are potent antigen-presenting cells. OK432 (Picibanil(R)) was introduced as a potent stimulator of DC maturation in combination with prostaglandin-E2 and interferon-alpha. We compared the efficacy of a DC-prostate cancer vaccine using early-mature DCs stimulated with OK432, PGE2 and INF-alpha (OPA) with that of vaccines using other methods. On days 3 or 7 of DC culture, TNF-alpha (T), TNF-alpha and LPS (TL) or OPA were employed as maturation stimulators. DU145 cells subjected to heat stress were hybridized with mature DCs using polyethyleneglycol. T cells were sensitized by the hybrids, and their proliferative and cytokine secretion activities and cytotoxicity were measured. The yields of early-mature DCs were higher, compared to yields at the conventional maturation time (P<0.05). In the early maturation setting, the mean fusion ratios, calculated from the fraction of dual-positive cells, were 13.3%, 18.6%, and 39.9%, respectively (P=0.051) in the T only, TL, and OPA-treated groups. The function of cytotoxic T cells, which were sensitized with the hybrids containing DCs matured early with OPA, was superior to that using other methods. The antitumor effects of DC-DU145 hybrids generated with DCs subjected to early maturation with the OPA may be superior to that of the hybrids using conventional maturation methods.
Cancer Vaccines/*immunology
;
Cell Line, Tumor
;
Dendritic Cells/cytology/drug effects/*immunology
;
Dinoprostone/*pharmacology
;
Humans
;
Immunologic Factors/*pharmacology
;
Interferon-alpha/*pharmacology
;
Lipopolysaccharides/toxicity
;
Male
;
Neoplasms, Hormone-Dependent/*immunology
;
Phenotype
;
Picibanil/*pharmacology
;
Prostatic Neoplasms/*immunology
;
T-Lymphocytes, Cytotoxic/immunology